Microbio Co., Ltd. (4128) Stock Price & Analysis
4128 Stock Chart & Stats
- Day’s Range
- TWD 12.35 - TWD 13.45
- 52-Week Range
- TWD 12.35 - TWD 22.80
- Previous Close
- TWD 13.55
- Volume
- N/A
- Average Volume (3M)
- 1.03M
- Market Cap
- TWD 7.71B
- Enterprise Value
- TWD 8.50B
- Total Cash (Recent Filing)
- TWD 2.84B
- Total Debt (Recent Filing)
- TWD 709.48M
- Price to Earnings (P/E)
- 15.3
- Beta
- 0.50
- Next Earnings
- Mar 04, 2027 (Est.)
- EPS Estimate
- N/A
- Last Dividend Ex-Date
- Jun 16, 2023
- Dividend Yield
- N/A
4128 FAQ
What was Microbio Co., Ltd.’s price range in the past 12 months?
What is Microbio Co., Ltd.’s market cap?
When is Microbio Co., Ltd.’s upcoming earnings report date?
How were Microbio Co., Ltd.’s earnings last quarter?
Is Microbio Co., Ltd. overvalued?
Does Microbio Co., Ltd. pay dividends?
What is Microbio Co., Ltd.’s EPS estimate?
How many shares outstanding does Microbio Co., Ltd. have?
What happened to Microbio Co., Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Microbio Co., Ltd.?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Microbio Co., Ltd.
Microbio Co., Ltd., established in 2000 and headquartered in Taipei, Taiwan, functions as a comprehensive biotechnology enterprise. The company's core activities involve the research, development, manufacturing, and commercialization of advanced biopharmaceutical drugs and nutritional supplements within Taiwan. Currently, Microbio offers two key products: MS-20, designed to alleviate fatigue and appetite loss experienced by cancer patients undergoing chemotherapy, and Herbiron, aimed at addressing symptoms linked to iron deficiency anemia and menstrual discomfort. Its robust drug pipeline includes several compounds in various stages of development. In the preclinical phase, the company is developing SNA-03 and SNA-07 for cancer immunotherapy, SNP-630 for non-alcoholic steatohepatitis (NASH), FB918 targeting non-allergic eosinophilic asthma, and SNS812 as an investigational treatment for Cov-flu. Moving into Phase I clinical trials, Microbio is advancing OB-318 as an anti-cancer agent, MB-110 for hepatitis C therapy, SNP-810 as an acetaminophen alternative, FB317 for moderate-to-severe allergic asthma and chronic idiopathic urticaria, and FB704A, which is being explored for conditions like rheumatoid arthritis, certain cancers, and cytokine storms. Furthermore, FB825 is currently undergoing Phase II clinical assessment for its potential in treating atopic dermatitis, allergic asthma, hyper IgE syndrome, and various food allergies. In its late-stage development, Microbio has two products in Phase III trials: ON101, designed to treat diabetic foot ulcers, and MB-6, an adjuvant therapy for metastatic colorectal cancer. The discovery pipeline holds additional candidates such as FB121 for AIDS, SNA01 for PD-1 related cancers, SNA02 for cancer immunotherapy, and SNS01 targeting recurrent metastatic non-small cell lung cancer. Additionally, Microbio is developing SNP-830 and SNP-840, novel analgesics designed to be free from hepatotoxicity. Beyond pharmaceuticals, Microbio diversifies its operations through organic food trading, beverage sales, technology development and transfer services, consulting, and even magazine publishing.
- Sector
- General
- Industry
- Medical - Pharmaceuticals
- CEO
- Tzen-Wen Chen
- Employees
- 577
- Website
- www.twmicrobio.com
- Address
- No. 3, Park St., Taipei, TP, 115, TW
Microbio Co., Ltd. (4128) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 14 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 0 | 0 | 12 |
